# Ipamorelin Dosage in Research: Doses Studied, Routes, and Half-Life > Ipamorelin dosage as studied in research: the doses, routes, and ~2-hour half-life recorded in the literature. Research-context only, third person, no human dosing guidance. What was administered, to which species, by which route, in published studies. No human dosing guidance. ## The short version This page describes ipamorelin dosage the way the studies report it — what researchers gave to animals or volunteers, and how the body cleared it — and nothing more. It is not a how-to and it carries no recommendation for any person. The numbers that are solid are the pharmacokinetic ones: in humans, ipamorelin has a terminal half-life of about 2 hours, and the growth-hormone pulse it triggers peaks roughly 40 minutes after a dose [2]. The animal doses span a wide range depending on what was being measured — bone growth, body weight, or chemotherapy-related weight loss [4][5]. The popular CJC-1295 plus ipamorelin "stack" protocols circulating online have no peer-reviewed human dosing basis; they are community conventions, described here as anecdotal, not as instructions. ## Doses studied, by model In the human pharmacokinetic study, single intravenous doses of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg were infused over 15 minutes [2]. In the only human Phase 2 efficacy trial, the dose was 0.03 mg/kg intravenously twice daily for up to seven days [3]. In rodent body-composition work, the bone-growth study used 18, 90, and 450 μg/day subcutaneously, divided three times daily over 15 days [4], and a bone-mineral study used 0.5 mg/kg/day by continuous subcutaneous osmotic minipump for 12 weeks. The 2024 ferret cachexia study used 1 to 3 mg/kg intraperitoneally [5]. These figures are reported here as study parameters in named species — they are not converted to, and must not be read as, a human dose. ## Routes studied Ipamorelin has been administered intravenously (the route in human pharmacokinetic and clinical work, and in much rodent efficacy testing), subcutaneously (the dominant route in rodent bone and body-composition studies, and in community use), intranasally (rodent pharmacokinetics, with about 20% bioavailability [11]), and intraperitoneally (rodent and ferret efficacy studies [5]). Oral administration applies only to engineered ipamorelin-derived analogs — roughly 10% bioavailable in dogs for one lead compound [13] — because ipamorelin itself is not orally bioavailable. Route matters because it shapes how much intact peptide reaches the circulation and how the growth-hormone pulse is timed. ## How long does ipamorelin stay in your system In healthy human volunteers, ipamorelin showed a terminal half-life of approximately 2 hours, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response is a single discrete pulse peaking about 40 minutes (0.67 h) after dosing, not a sustained elevation [2]. As a half-life of roughly 2 hours, the parent peptide is largely cleared within a day; in rats, plasma clearance is about 5-fold lower than GHRP-6, and 60 to 80% of a dose is recovered intact in bile and urine [11]. These are measured pharmacokinetic values, not a guide to timing any personal use. ## How much cjc-1295 ipamorelin should i take There is no peer-reviewed human dose for the CJC-1295 plus ipamorelin combination, so no responsible figure can be given. The combination has never been tested in a controlled human trial for any outcome, and the single combination-specific result in the literature is a murine muscle-loss study, not a human dosing study [16]. The protocols shared in peptide communities are anecdotal conventions without controlled-trial support and are not reproduced here as guidance. What the literature does provide is single-agent ipamorelin pharmacokinetics — a ~2-hour half-life and a ~40-minute growth-hormone pulse [2] — which is mechanism, not a prescription. ## How to reconstitute cjc-1295 ipamorelin 5mg Ipamorelin is supplied as a lyophilized (freeze-dried) powder, as either the free base or the acetate salt, and is reconstituted with bacteriostatic water for research handling. As a peptide it degrades with heat and repeated freeze-thaw cycles, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations drawn from the research-supply literature, not a clinical preparation instruction and not a directive for any human use. The specific volume used to reconstitute a given vial is a laboratory handling choice, not a dose this site endorses. --- A dark-mode evidence console for the ipamorelin record — the selective growth-hormone pulse logged where the studies confirm it, the body-composition signal read off the rodent data alone, and the single failed human trial posted in plain sight; no clinic behind the panel and nothing here dosed, sourced, or sold.